Menu Search
Equities

Dawnrays Pharmaceutical (Holdings) Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2348:HKG.HS

Dawnrays Pharmaceutical (Holdings) Ltd

Actions
  • Price (HKD)1.21
  • Today's Change0.03 / 2.54%
  • Shares traded36.00k
  • 1 Year change+0.83%
  • Beta0.2615
Data delayed at least 15 minutes, as of Feb 16 2026 03:23 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Dawnrays Pharmaceutical (Holdings) Ltd is an investment holding company mainly engaged in the development, manufacture and sale of non-patented drugs. The Company operates its business through two segments. The finished drugs segment is engaged in the manufacture and sale of finished drugs. The intermediates and bulk medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines.

  • Revenue in HKD (TTM)1.26bn
  • Net income in HKD199.64m
  • Incorporated2002
  • Employees1.12k
  • Location
    Dawnrays Pharmaceutical (Holdings) LtdUnits 3001-02, 30/F, CNT Tower, Wanchai Hong KongHKG
  • Phone+852 21119708
  • Fax+852 21119870
  • Websitehttps://www.dawnrays.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.